Oxford Biomedica (OXB) Competitors

Oxford Biomedica (LON:OXB) and Genus (LON:GNS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.

Does the media prefer OXB or GNS?

In the previous week, Genus had 7 more articles in the media than Oxford Biomedica. MarketBeat recorded 8 mentions for Genus and 1 mentions for Oxford Biomedica. Genus' average media sentiment score of 0.40 beat Oxford Biomedica's score of 0.00 indicating that Genus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genus	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, OXB or GNS?

Oxford Biomedica has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Genus has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Do analysts rate OXB or GNS?

Oxford Biomedica currently has a consensus target price of GBX 410, indicating a potential upside of 20.23%. Genus has a consensus target price of GBX 2,150, indicating a potential upside of 13.16%. Given Oxford Biomedica's higher possible upside, equities analysts plainly believe Oxford Biomedica is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Genus	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable earnings & valuation, OXB or GNS?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£89.54M	4.01	-£157.49M	-£1.63	-209.20
Genus	£668.80M	1.86	£7.90M	£0.12	15,833.33

Does the MarketBeat Community favor OXB or GNS?

Oxford Biomedica received 8 more outperform votes than Genus when rated by MarketBeat users. However, 70.62% of users gave Genus an outperform vote while only 66.85% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Oxford Biomedica	Outperform Votes 359 66.85%	Underperform Votes 178 33.15%
Genus	Outperform Votes 351 70.62%	Underperform Votes 146 29.38%

Do institutionals and insiders hold more shares of OXB or GNS?

57.5% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 80.2% of Genus shares are owned by institutional investors. 20.6% of Oxford Biomedica shares are owned by company insiders. Comparatively, 0.6% of Genus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is OXB or GNS more profitable?

Genus has a net margin of 1.18% compared to Oxford Biomedica's net margin of -175.89%. Genus' return on equity of 0.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-175.89%	-117.29%	-15.08%
Genus	1.18%	0.43%	3.31%

Summary

Genus beats Oxford Biomedica on 12 of the 17 factors compared between the two stocks.